Remanded
EB-1C
EB-1C Remanded — Clinical Medical Trials (2022): the Director did not sufficiently consider the totality of
Decision Summary
The appeal was remanded because the Director did not sufficiently consider the totality of the evidence submitted in response to the Notice of Intent to Revoke (NOIR). The AAO found that the Director's decision overlooked substantial evidence establishing the petitioner was 'doing business' and improperly analyzed its ability to pay the proffered wage.
Criteria Discussed
Doing Business Ability To Pay Managerial Or Executive Capacity Viability Of Business
📄 Original decision (USCIS PDF)
Sign up free to download the original PDF
Downloaded the case? Use it in your next draft →Research more EB-1C decisions on MeritDraft
Browse AAO decisions by visa type, outcome, and criteria discussed.
Browse Decisions →